Results 61 to 70 of about 795 (185)

Glutaminase‐1 Mediated Glutaminolysis to Glutathione Synthesis Maintains Redox Homeostasis and Modulates Ferroptosis Sensitivity in Cancer Cells

Cell Proliferation, Volume 58, Issue 11, November 2025.
GLS1‐mediated glutaminolysis supports GSH synthesis in cancer cells. GLS1 KO increases ROS, downregulates GPX4, and upregulates GPX1, making cells more sensitive to ferroptosis. Combining GLS1 or GPX1 inhibitors with a GPX4 inhibitor synergistically suppresses cancer growth.
Changsen Bai, Jialei Hua, Donghua Meng, Yue Xu, Benfu Zhong, Miao Liu, Zhaosong Wang, Wei Zhou, Liming Liu, Hailong Wang, Yang Liu, Lifang Li, Xiuju Chen, Yueguo Li   +13 more
wiley   +1 more source

Cp*Co(III)‐catalyzed C–H functionalization of bioactive heterocyclic motifs

Bulletin of the Korean Chemical Society, Volume 46, Issue 6, Page 622-635, June 2025.
Directed carbon–hydrogen bond functionalization of biologically active scaffolds is attractive as it enables the selective modification of sophisticated structures, enhancing the efficiency of drug development by adopting diverse functional groups. This review summarizes recent advances in cobalt‐catalyzed C–H functionalizations of bioactive motifs ...
Yeongmi Park, Junbeom Park, Yong Ho Lee, Jongwoo Son   +3 more
wiley   +1 more source

High prominence:Low prominence ratios over time.

, 2015
(A) capecitabine, (B) eldecalcitol, (C) epoetin beta pegol, (D) peginterferon alfa-2a, and (E) sevelamer hydrochloride.
Seigo Okugawa (733308), Kotonari Aoki (733302), Terumi Nakayama (733307), Takumi Kobayashi (733305), Takuya Kawamata (733303), Minami Tomita (733310), Yoshihiko Sugimura (733309), Yoichiro Takahashi (733311), Hiroshi Kuriki (733306), Shinichi Matsuda (733301), Tetsuji Kimotsuki (733304)   +10 more
core   +1 more source

Effects of monthly minodronate with or without eldecalcitol addition in osteoporosis patients with rheumatoid arthritis: An 18-month prospective study

Osteoporosis and Sarcopenia, 2019
Objectives: Increasing bone mineral density (BMD) to reduce fracture risk is a primary goal of osteoporosis treatment. This prospective, observational study evaluates the effects of monthly minodronate (MIN; 50 mg) with or without eldecalcitol (ELD ...
Takako Suzuki, Yukio Nakamura, Hiroyuki Kato   +2 more
doaj   +1 more source

Antisenescence therapies for age‐related bone loss: Target factors, medicines, biomedical materials

Clinical and Translational Medicine, Volume 15, Issue 6, June 2025.
With extended lifespans causing population aging, bone aging has become a worldwide issue. Cellular senescence in the bone microenvironment causes bone degeneration and dysfunction. This review summarises targets in cellular senescence and bone aging while detailing potential therapeutic strategies, including novel medicines and innovative biomedical ...
Qiyue Zhu, Menglong Hu, Likun Wu, Erfan Wei, Xingtong Pan, Hao Liu, Yunsong Liu   +6 more
wiley   +1 more source

Serious: Non-serious ratios over time.

, 2015
(A) capecitabine, (B) eldecalcitol, (C) epoetin beta pegol, (D) peginterferon alfa-2a, and (E) sevelamer hydrochloride.
Seigo Okugawa (733308), Kotonari Aoki (733302), Terumi Nakayama (733307), Takumi Kobayashi (733305), Takuya Kawamata (733303), Minami Tomita (733310), Yoshihiko Sugimura (733309), Yoichiro Takahashi (733311), Hiroshi Kuriki (733306), Shinichi Matsuda (733301), Tetsuji Kimotsuki (733304)   +10 more
core   +1 more source

Safety and Efficacy of Zoledronic Acid Treatment with and without Acetaminophen and Eldecalcitol for Osteoporosis

Internal Medicine, 2021
Objectives We aimed to investigate the safety of zoledronic acid (ZOL) combined with acetaminophen (APAP) regarding both the adverse events and the efficacy of ZOL combined with an eldecalcitol (ELD) in a randomized clinical trial conducted in patients with primary osteoporosis.
Mochizuki, Takeshi, Yano, Koichiro, Ikari, Katsunori, Okazaki, Ken   +3 more
openaire   +3 more sources

Additive effects of eldecalcitol in poorly responding long-term bisphosphonate treatment for osteoporosis

Osteoporosis and Sarcopenia, 2019
Objectives: We examined whether eldecalcitol (ELD) provided additive bone mineral density (BMD) and bone turnover marker gains in patients undergoing long-term bisphosphonate (BP) usage, especially in osteoporotic individuals exhibiting a poor response ...
Mikio Kamimura, Shota Ikegami, Keijiro Mukaiyama, Hidefumi Koiwai, Yukio Nakamura, Akira Taguchi, Hiroyuki Kato   +6 more
doaj   +1 more source

Comprehensive Study of the Risk Factors for Medication-Related Osteonecrosis of the Jaw Based on the Japanese Adverse Drug Event Report Database

Pharmaceuticals, 2020
Medication-related osteonecrosis of the jaw (MRONJ) is associated with many drugs, including bisphosphonates (BPs). BPs are associated with atypical femoral fractures and osteonecrosis of the external auditory canal.
Shinya Toriumi, Akinobu Kobayashi, Yoshihiro Uesawa   +2 more
doaj   +1 more source

Recent Advances in Sustainable Total Synthesis and Chiral Pool Strategies with Emphasis on (−)‐Sclareol in Natural Products Synthesis

European Journal of Organic Chemistry, Volume 28, Issue 8, February 24, 2025.
There are continuous efforts to improve total syntheses of natural products, particularly their sustainability, such as developing effective chiral pool approaches relying on a wide spectrum of natural chirons, including (−)‐sclareol as one of the most useful natural chirons.
Ayyoub Selka, Abdelnasser Abidli, Lucie Schiavo, Loïc Jeanmart, Gilles Hanquet, William D. Lubell   +5 more
wiley   +1 more source